Home ›
Marginal Zone Lymphoma Lymphoma Trials ›
NCT07022223
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
This is a single-arm, prospective clinical study to evaluate the efficacy and safety of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.
Trial Details
NCT ID NCT07022223
Phase PHASE2
Sponsor Second Affiliated Hospital, Zhejiang University, School of Medicine
Status RECRUITING
Cancer Type Marginal Zone Lymphoma Lymphoma
Interventions orelabrutinib combined with rituximab regimen
Locations (sample) Hangzhou, Zhejiang, China|30.29365,120.16142 Dongyang, China|29.26778,120.22528 Hangzhou, China|30.29365,120.16142 Hangzhou, China|30.29365,120.16142 Huzhou, China|30.8703,120.0933
Key Eligibility Criteria
Age ≥ 18 years, regardless of gender; Histologically confirmed CD20-positive marginal zone lymphoma, including MALT, SMZL, and NMZL, with at least one lesion outside the spleen measurin… MZL that has progressed or relapsed after prior local therapy (including surgery, radiotherapy, anti-Helicobacter pylori treatment, and anti-hepati… ECOG performance status of 0-2;
For full eligibility, visit ClinicalTrials.gov .